Parkin J L
Otolaryngol Head Neck Surg. 1985 Feb;93(1):132-3. doi: 10.1177/019459988509300129.
A new antifungal agent, ketoconazole, has been added to the drugs available for the treatment of fungal infections. Ketoconazole has been shown to be effective in the treatment of mucocutaneous candidiasis with a reported 97% positive response rate. This drug may be administered orally to outpatients with a low risk of toxicity. Hepatitis has been reported as a possible complication of treatment. Infection relapse is the most significant posttherapeutic problem. Five patients suffering from mucocutaneous candidiasis after irradiation therapy are reported to have had favorable responses. The other available antifungal agents are reviewed and discussed.
一种新型抗真菌药物酮康唑已被添加到可用于治疗真菌感染的药物中。酮康唑已被证明对治疗黏膜皮肤念珠菌病有效，报告的阳性反应率为97%。这种药物可口服给药，用于毒性风险较低的门诊患者。已有报告称肝炎可能是治疗的并发症。感染复发是治疗后最严重的问题。据报道，5例接受放射治疗后患有黏膜皮肤念珠菌病的患者反应良好。本文对其他可用的抗真菌药物进行了综述和讨论。
